Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 974-981

  Gupta, Amit ^a   Kumar, Anil ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tertahydropyridine (MPTP); Cyclooxygenase (COX); Neuroinflammation; NS 398; Parkinson's disease; Valdecoxib

Indexed keywords

CASPASE 3; ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); VALDECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INDUCTION; LIPID PEROXIDATION; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASPASE 3; CATATONIA; CYCLOOXYGENASE 2 INHIBITORS; INFLAMMATION; ISOXAZOLES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MICE; MITOCHONDRIA; MOTOR ACTIVITY; MPTP POISONING; NADH DEHYDROGENASE; NEUROPROTECTIVE AGENTS; NITRITES; NITROBENZENES; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS; SULFONAMIDES; TETRAZOLIUM SALTS; THIAZOLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSCRIPTION FACTOR RELA;

EID: 79955999259     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.01.017     Document Type: Article

References (36)

1. Aguirre J.A., Leo G., Cueto R., Andbjer B., Naylor A., Medhurst A.D., et al. The novel cyclooxygenase-2 inhibitor GW637185x protects against l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. NeuroReport 2008, 19:657-660.
2. Bartels A.L., Leenders K.L. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 2007, 22:1852-1856.
3. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999, 73:1127-1137.
4. Dannhardt G., Kiefer W. Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem 2001, 36:109-126.
5. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
6. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949, 177:751-766.
7. Gupta A., Dhir A., Kumar A., Kulkarni S.K. Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. Pharmacol Biochem Behav 2009, 94:219-226.
8. Gupta A., Dhir A., Kumar A., Kulkarni S.K. Effect of preferential cyclooxygenase-2 (COX-2) inhibitor against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal lesions in rats: Behavioral, biochemical and histological evidences. Indian J Exp Biol 2010, 48:577-585.
9. Gupta A., Kumar A., Kulkarni S.K. Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidences. Inflammopharmacol 2010, 18:223-232.
10. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992, 59:1609-1623.
11. Huff R., Collins P., Kramer S., Seibert K., Koboldt C., Gregory S., et al. A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX2). Inflamm Res 1995, 44(Supplement 2):S145-S146.
12. King T.E., Howard R.L. Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 1967, 10:275-294.
13. Kulkarni S.K., Dhir A. Cyclooxygenase in epilepsy: from perception to application. Drugs Today 2009, 45:135-154. (Barc).
14. Kumar A., Kumari B., Kumar P. Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress. Neurosci Bull 2010, 26:17-27.
15. Kumar P., Padi S.S., Naidu P.S., Kumar A. Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol 2007, 21(3):297-306.
16. Liu H.Q., Zhang W.Y., Luo X.T., Ye Y., Zhu X.Z. Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. Br J Pharmacol 2006, 148:314-325.
17. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-910.
18. Monahan A.J., Warren M., Carvey P.M. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant 2008, 17:363-372.
19. Mosmann T. Rapid colorimetric assay for cellular growth survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983, 65:55-63.
20. Murray J., Taylor S.W., Zhang B., Ghosh S. Oxidative damage to mitochondrial complex I due to peroxynitrite. J Biol Chem 2003, 278:37223-37230.
21. Nagayama M., Niwa K., Nagayama T., Ross M.E., Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999, 19:1213-1219.
22. Nogawa S., Zhang F., Ross M.E., Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 17:2746-2755.
23. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
24. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007, 42:3-27.
25. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008, 11:81s-110s.
26. Reksidler A.B., Lima M.M., Zanata S.M., Machado H.B., da Cunha C., Andreatini R., et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007, 560:163-175.
27. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005, 134:57-66.
28. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996, 40:663-671.
29. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39:167-174.
30. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993, 61:1191-1206.
31. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 2003, 4:365-375.
32. Vila M., Ramonet D., Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008, 107:317-328.
33. Vroon A., Drukarch B., Bol J.G., Cras P., Breve J.J., Allan S.M., et al. Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 2007, 42:762-771.
34. Watanabe Y., Kato H., Araki T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metab Brain Dis 2008, 23:51-69.
35. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003, 100:6145-6150.
36. Yokoyama H., Kuroiwa H., Yano R., Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008, 29:293-301.